Yosemite Pathology & Precision Pathology Company Profile

Background

Yosemite Pathology & Precision Pathology is a physician-owned pathology group with a CLIA-certified and College of American Pathologists (CAP) accredited anatomic pathology laboratory. Established in 1948 by Dr. Jeanne Miller, a UCSF-trained pathologist, the organization has been dedicated to providing comprehensive and superior diagnostic services to physicians and hospitals, aiming to enhance patient care through advanced technological solutions.

Key Strategic Focus

The company's strategic focus centers on delivering high-quality anatomic and clinical pathology services across a broad range of specialties. With over 35 board-certified pathologists, Yosemite Pathology & Precision Pathology serves as laboratory medical directors in more than 20 hospitals, offering expertise in various subspecialties. The organization emphasizes innovation, quality, compassion, and integrity, striving to meet the evolving needs of its clients and the communities it serves.

Financials and Funding

As of May 2025, Yosemite Pathology & Precision Pathology reported an estimated annual revenue of approximately $15 million, with a workforce of around 68 employees. The company's revenue per employee is estimated at $243,000, reflecting efficient operations within the healthcare industry.

Pipeline Development

In response to the COVID-19 pandemic, Yosemite Pathology & Precision Pathology developed and offered the "Aptima SARS-CoV-2 Assay," a test designed to detect the coronavirus. This assay, manufactured by Hologic Diagnostics, was submitted for Emergency Use Authorization (EUA) and demonstrated the company's commitment to addressing emergent healthcare challenges.

Technological Platform and Innovation

The organization employs advanced technological platforms to enhance diagnostic accuracy and efficiency. Their laboratory is equipped with state-of-the-art instrumentation, enabling the processing of over 750 COVID-19 tests every 16 hours during the pandemic. This capacity underscores their commitment to leveraging technology for improved patient outcomes.

Leadership Team

Jennifer Pinasco, CEO: Joined the company in 1996, progressing through various roles to become CEO. She emphasizes compassionate, quality-focused pathology services and has been instrumental in fostering a culture of innovation and employee engagement.

Anthony R. Victorio, M.D., Medical Director: Provides medical leadership and oversees the delivery of pathology services, ensuring adherence to the highest standards of quality and patient care.

Emad Kaabipour, M.D., Medical Director: Co-leads the medical direction, focusing on integrating advanced diagnostic techniques and maintaining excellence in pathology services.

Leadership Changes

In October 2020, Yosemite Pathology & Precision Pathology expanded its leadership team through the acquisition of Bakersfield Pathology Medical Group (BPMG). This strategic move integrated BPMG's pathologists and staff, enhancing the organization's diagnostic and consulting services.

Competitor Profile

Market Insights and Dynamics

The anatomic pathology market is characterized by a growing demand for accurate and timely diagnostic services, driven by advancements in personalized medicine and an aging population. The integration of molecular diagnostics and digital pathology is reshaping the industry, emphasizing the need for innovation and adaptability.

Competitor Analysis

CellNetix Pathology & Laboratories: Based in Tukwila, Washington, CellNetix is a prominent anatomic pathology provider in the Pacific Northwest, offering services such as cytology, histology, and molecular diagnostics. They employ a subspecialized case allocation process and have invested in whole-slide imaging technology.

American Pathology Partners (APP): Headquartered in Nashville, Tennessee, APP operates a nationwide network of pathology laboratories, providing sub-specialized anatomic and molecular pathology services. They have expanded through acquisitions, including UniPath in Denver and Eastern Carolina Pathology in North Carolina.

Myriad Genetics: A Salt Lake City-based company specializing in genetic testing and precision medicine, Myriad offers prognostic tests like "Prolaris" for prostate cancer and "myRisk Hereditary Cancer" for assessing hereditary cancer risk. They have expanded their portfolio through acquisitions, including Assurex Health and Counsyl.

Strategic Collaborations and Partnerships

In August 2018, Precision Pathology partnered with Outpatient Pathology Associates (OPA) to enhance diagnostic and consulting services. This collaboration expanded the spectrum of subspecialty skills and improved integration of information technology and report delivery.

In October 2020, the acquisition of Bakersfield Pathology Medical Group further strengthened the organization's market position, allowing for an expanded geographic reach and enhanced service offerings.

Operational Insights

Yosemite Pathology & Precision Pathology differentiates itself through a commitment to quality, compassion, integrity, and innovation. The organization fosters a positive workplace culture, with 82% of employees considering it a great place to work, compared to 57% at a typical U.S.-based company. This employee satisfaction contributes to high-quality service delivery and client satisfaction.

Strategic Opportunities and Future Directions

The company aims to continue its expansion through strategic acquisitions of small physician group practices, both interstate and intrastate, to broaden its service offerings and geographic reach. Additionally, there is a focus on developing career path programs in pathology to cultivate the next generation of pathology leaders and address workforce needs.